ReviewCancer innovation2023
Advances in medical treatment of breast cancer in 2022.
Review in Cancer innovation, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Oral herbal medicine for breast cancer-related symptoms: an evidence map of systematic reviews.Frontiers in medicine · 2026Pooled it
- Cancer mortality in Europe in 2020, and an overview of trends since 1990.European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP) · 2026Article
- DCBLD1 as a novel prognostic biomarker and therapeutic target in breast cancer: clinical validation and mechanistic insights.Annals of medicine and surgery (2012) · 2026Article
- Gambogic acid-loaded transferrin-modified liposomes enhancing potent ferroptosis in breast cancer.Scientific reports · 2026Article
- Oncosexology: A Narrative Review on Sexual Health and Quality of Life in Cancer Patients.Cancer medicine · 2026Review
- Synergistic Effects of CoHCF@MWCNTs@FA Nanocomposites Enhancing Photodynamic Therapy for Triple-Negative Breast Cancer.ACS omega · 2026Article
- Potential Targets and Biomarkers of Radionuclide Therapy in Breast Cancer.Cancer innovation · 2026Review
- Electroacupuncture for Managing Chemotherapy-Induced Gastrointestinal Symptom Clusters in Patients With Breast Cancer: Study Protocol for a Randomized Controlled Trial.Health care science · 2026Article
- Machine Learning Model Based on Multiparametric MRI for Distinguishing HER2 Expression Level in Breast Cancer.Current oncology (Toronto, Ont.) · 2026Article
- Recent advances in research on the multifactorial mechanisms underlying paclitaxel resistance and translational intervention strategies.Frontiers in pharmacology · 2026Review
- Tumor Suppressor p53 and MicroRNAs Interaction in Breast Cancer.Oncology research · 2026Review
- Efficacy, safety, and biomarkers of neoadjuvant trastuzumab and pertuzumab combined with chemotherapy in Chinese patients with HER2-positive breast cancer: a multicenter retrospective cohort study.International journal of surgery (London, England) · 2026Article
- A Systematic Review of Methods to Measure Adherence to Oral Anticancer Medications in African Women With Breast Cancer at Initiation, Implementation, and Discontinuation of Therapy.International journal of breast cancer · 2026Review
- Clinicopathological characteristics and prognostic analysis of multifocal/multicentric breast cancer.Scientific reports · 2025Article
- Article
- Defeating miR-181a-3p may potentiate the effect of paclitaxel on G2/M arrest in breast cancer stem cells.Medical oncology (Northwood, London, England) · 2025Article
- Article
- The Identification of Novel Prognostic and Predictive Biomarkers in Breast Cancer via the Elucidation of Tumor Ecotypes Using Ecotyper.Cancer innovation · 2025Article
- Cyclin dependent kinase 9 inhibitor induces transcription-replication conflicts and DNA damage accumulation in breast cancer.Cancer cell international · 2025Article
- An Exploratory Retrospective Analysis of Racial Disparities in Fall-Related Injuries Among Black and White Breast Cancer Survivors Receiving Chemotherapy.International journal of environmental research and public health · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Breast cancer has replaced lung cancer as the most common malignancy worldwide. The 5-year survival rate of breast cancer has reached 90%. Systemic treatment of breast cancer has developed into a mature system including chemotherapy, targeted therapy, endocrine therapy and immunotherapy. This article summarizes the annual progress of breast cancer chemotherapy, targeted therapy, endocrine therapy and immunotherapy in 2022, providing valuable information for future research to better guide individualized treatment of breast cancer, thereby improving the prognosis and quality of life of breast cancer patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.